Ipilimumab, vemurafenib, dabrafenib, and trametinib: Synergistic competitors in the clinical management of BRAF mutant malignantmelanoma

Oncologist

Volumn 18, Issue 6, 2013, Pages 717-725

  Luke, Jason J ^a   Hodia, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Biomarker; BRAF; CTLA 4; Immunotherapy; MEK; Resistance

Indexed keywords

B RAF KINASE; CD28 ANTIGEN; DABRAFENIB; DACARBAZINE; GLYCOPROTEIN GP 100; INTERLEUKIN 17; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; TRAMETINIB; VASCULOTROPIN; VEMURAFENIB;

ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CENTRAL SEROUS RETINOPATHY; CHORIORETINOPATHY; COLITIS; DERMATITIS; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOXICITY; EYE TOXICITY; FATIGUE; FEVER; FOLLOW UP; GENE MUTATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; MELANOMA; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DEFECT; SKIN PAPILLOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

BIOMARKER; BRAF; CTLA-4; IMMUNOTHERAPY; MEK; RESISTANCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INDOLES; MAP KINASE KINASE KINASES; MELANOMA; MUTATION; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SULFONAMIDES;

EID: 84879467934     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0391     Document Type: Article

References (72)

1. Coit DG, Andtbacka R, Anker CJ et al. Melanoma. J Natl Compr Canc Netw 2012;10:366-400.
2. Peggs KS, Segal NH, Allison JP. Targeting immu-nosupportive cancer therapies: Accentuate the positive, eliminate the negative. Cancer Cell 2007; 12:192-199.
3. Melero I, Hervas-Stubbs S, Glennie M et al. Im-munostimulatorymonoclonalantibodies forcancer therapy. Nat Rev Cancer2007;7:95-106.
4. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emergingclass of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-5283.
5. Leach DR, Krummel MF, Allison JP. Enhance ment of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.
6. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-366.
7. Hurwitz AA, Foster BA, Kwon EDet al. Combina-tionimmunotherapyofprimaryprostatecancerina transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-2448.
8. van Elsas A, Sutmuller RP, Hurwitz AA et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J Exp Med 2001;194:481-489.
9. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4antibodyblockade in previouslyvaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712-4717.
10. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA2003;100:8372-8377.
11. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 2010;21:1712-1717.
12. Wolchok JD, Neyns B, Linette G et al. Ipili-mumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
13. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, phase II studycomparingthetolerabilityand efficacyofip-ilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598.
14. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
15. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
16. Robert C, Thomas L, Bondarenko I et al. Ipili-mumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-2526.
17. Bouwhuis MG, Ten Hagen TL, Suciu S et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2011;23:170-176.
18. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23: 6043-6053.
19. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical responsein patients with metastatic melanoma treated by CTL-associ-ated antigen-4 blockade. Clin Cancer Res 2007;13: 6681-6688.
20. Wolchok JD, Weber JS, Hamid O et al. Ipili-mumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from fourtrials. Cancer Immun 2010;10:9.
21. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, aselective inhibitorof native and mutant Bcr-Abl. Cancer Cell 2005;7: 129-141.
22. Yuan J, Adamow M, Ginsberg BA et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA2011;108:16723-16728.
23. Ku GY, Yuan J, Page DB et al. Single-institution experiencewith ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer2010;116:1767-1775.
24. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Can-cer Res2012;18:2039-2047.
25. Sabatino M, Kim-Schulze S, Panelli MCet al. Se-rum vascular endothelial growth factor and fi-bronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-2652.
26. Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: Potential inroads to improved immunotherapy. J Clin Oncol 2009;27:2583-2585.
27. Hodi FS, Friedlander PA, Atkins MB et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011;29(suppl; abstr 8511).
28. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011;71: 5445-5454.
29. Hamid O, Schmidt H, Nissan Aet al. Aprospec-tive phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011;9:204.
30. Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immu-nother2012;61:1019-1031.
31. Huang RR, Jalil J, Economou JS et al. CTLA4 blockade induces frequenttumorinfiltration byactivated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011;17:4101-4109.
32. Ribas A, Comin-Anduix B, Economou JS et al. Intratumoral immune cell infiltrates, Fox P3, and in-doleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 2009;15:390-399.
33. Curtin JA, Fridlyand J, Kageshita Tet al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
34. Hauschild A, Agarwala SS, Trefzer U et al. Results ofa phase III, randomized, placebo-controlled studyofsorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-2830.
35. Eisen T, Marais R, Affolter A et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: Phase I and open-label phase II studies. Brit J Cancer 2011;105:353-359.
36. Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitorofoncogenic B-Rafkinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105:3041-3046.
37. Bollag G, Hirth P, Tsai J et al. Clinical efficacyof a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-599.
38. Flaherty KT, Puzanov I, Kim KBet al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
39. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. NEngl J Med 2012;366:707-714.
40. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
41. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC)in previouslyuntreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012;30(suppl):8502a.
42. Falchook GS, Long GV, Kurzrock R et al. Dab-rafenib in patientswith melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379:1893-1901.
43. Long GV, Trefzer U, Davies MA et al. Dab-rafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-1095.
44. Hauschild A, Grob JJ, Demidov LV et al. Dab-rafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
45. Joseph EW, Pratilas CA, Poulikakos PI et al. The RAF inhibitor PLX4032 inhibits ERK signalingand tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010;107:14903-14908.
46. Poulikakos PI, Zhang C, Bollag G et al. RAF in-hibitorstransactivate RAFdimersand ERKsignalling in cells with wild-type BRAF. Nature 2010;464:427-430.
47. Hatzivassiliou G, Song K, Yen I et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-435.
48. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209-221.
49. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215.
50. Pao W, Miller VA, Politi KAet al. Acquired resistance of lung adenocarcinomas to gefitinib or erlo-tinib is associated with a second mutation in the EGFR kinase domain. PLo S Med 2005;2:e73.
51. Shah NP, Tran C, Lee FY et al. Overriding ima-tinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
52. Nazarian R, Shi H, Wang Qet al. Melanomasac-quire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-977.
53. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-972.
54. Wagle N, Emery C, Berger MFet al. Dissecting therapeutic resistance to RAF inhibition in mela noma bytumorgenomic profiling. J Clin Oncol 2011; 29:3085-3096.
55. Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimeriza-tion of aberrantly spliced BRAF(V600E). Nature 2011;480:387-390.
56. Shi H, Moriceau G, Kong X et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724.
57. Straussman R, Morikawa T, Shee K et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature doi:10.1038/nature11183.
58. Wilson TR, Fridlyand J, Yan Y et al. Widespread potential for growth-factor-driven resistance to anti-cancerkinase inhibitors. Nature 2012;487:505-509.
59. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-1703.
60. Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitortrametinib: A phase 1 dose-escalation trial. Lancet Oncol 2012;13:773-781.
61. Falchook GS, Lewis KD, Infante JRet al. Activity ofthe oral MEK inhibitortrametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. Lancet Oncol 2012;13:782-789.
62. Flaherty KT, Robert C, Hersey Pet al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-114.
63. Kim KB, Kefford R, Pavlick AC et al. Phase II studyofthe MEK1/MEK2 inhibitortrametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-489.
64. Margolin K, Ernstoff MS, Hamid O et al. Ipili-mumab in patients with melanoma and brain me-tastases: An open-label, phase 2 trial. Lancet Oncol 2012;13:879-886.
65. Dummer R, Goldinger S, Turtschi Cet al. Open-label pilot study of vemurafenib in previously treated metastatic melanoma (MM) patients (pts) with symptomatic brain metastases (BM). Ann Oncol 2012;23(suppl):2720a.
66. Postow MA, Callahan MK, Barker CAet al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-931.
67. Das Thakur M, Salangsang F, Landman AS et al. Modelling vemurafenib resistance in melanoma re veals a strategy to forestall drug resistance. Nature 2013;494:251-255.
68. Chaft JE, Oxnard GR, Sima CS et al. Disease flare aftertyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res 2011; 17:6298-6303.
69. Ascierto PA, Simeone E, Giannarelli D et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithmforclinicaluse. JTransl Med 2012;10:107.
70. Ackerman A, McDermott DF, Lawrence DP et al. Outcomes of patients with malignant melanoma treated with immunotherapy priorto oraf-ter vemurafenib. J Clin Oncol 2012;30(suppl; abstr8569).
71. Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-5219.
72. Wilmott JS, Long GV, Howle JR et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-1394.